Serapha Bio takes flight from Boundless merger with $230M and gene-editing prospect from China on June 24, 2026 alpha 1-Antitrypsin Deficiency Base Editing Boundless Bio China Gene Modification in vivo Nasdaq Piperine Extract (Standardized) reverse merger Rheumatoid Arthritis Serapha Bio SERP-01 SERPINA1 gene YolTech +
China gene editing startup YolTech raises $70M to move CRISPR therapies forward on May 28, 2026 AGXT gene Amyloidosis China Clustered Regularly Interspaced Short Palindromic Repeats Gene Modification Hypercholesterolemia, Familial in vivo startup TTR wt Allele YolBE YolCas YolTech +